Wegovy 25 mg? Decoding the Number and the Real Schedule

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This explainer lives in the PlexusDx Education Hub. Browse every Peptides & GLP-1 guide for the wider library.

A search for "Wegovy 25 mg" almost always reflects a number that got garbled somewhere between a label, a screen, and a memory. Wegovy is dosed in small single-digit milligram amounts, so a plain "25 mg" is worth decoding before anything else. This page places the real numbers in order and explains what the labeled schedule contains, without giving prescribing or titration direction. The Education Hub holds the broader library.

Decoding the "25 mg" number

The Wegovy schedule uses strengths like 0.25 mg and 2.4 mg, and it is easy to see how a decimal point drops out and "0.25" becomes "25" in a hurried search. Wegovy (semaglutide 2.4 mg) is the FDA-approved weight-management brand of semaglutide, and its titration path runs 0.25, 0.5, 1.0, 1.7, and finally 2.4 mg as the maintenance dose. Whatever exact figure you meant, it lives somewhere on that ladder.

How the labeled schedule is built

The schedule is deliberately gradual. It opens at the lowest step so the body can adjust, then rises through the intermediate amounts before arriving at the maintenance strength. Each figure on the ladder is a specific point the label defines, not a rounded approximation, which is exactly why an off-by-a-decimal number can cause confusion. Reading the strengths precisely keeps the picture accurate.

What people report across the steps

Regardless of which step someone is on, gastrointestinal effects tend to lead the experience. Nausea, mild vomiting, and short-lived constipation or diarrhea are the most reported, usually strongest in the first weeks after a change in strength. Reduced appetite, earlier satiety, and smaller portions are also common. These are individual experiences, and clinical outcomes vary widely from person to person.

When a step changes

Intervals between strengths are set in each product's FDA label, commonly around four weeks, and adjusted by the prescribing clinician. Strong gastrointestinal symptoms may prompt a provider to hold at the current strength; good tolerance with unmet goals may prompt a move upward per the label. The clinician drives that decision using how the individual is actually responding rather than a fixed timetable.

Safety signals at any strength

Some symptoms deserve prompt attention at any point on the ladder: severe or persistent abdominal pain, right-upper-quadrant pain with fever, persistent vomiting with dehydration, signs of low blood sugar, or an allergic reaction. Severe symptoms warrant urgent or emergency care. Every GLP-1 receptor agonist and GIP/GLP-1 dual agonist carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies.

Genetics beneath the numbers

No matter which strength appears on a prescription, inherited biology shapes appetite, satiety, and energy balance in the background. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, GLP1R, MC4R, and TCF7L2 linked to baseline appetite and energy handling. This is pathway education from 503A-aligned testing. It does not predict your response to any dose and is not pharmacogenomic; it simply hands your clinician upstream context that applies across every step.

Protocols at PlexusDx

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, and Tirzepatide Injection. It does not sell or recommend other GLP-1 category peptides such as dulaglutide, liraglutide, retatrutide, or cagrilintide. Pairing a protocol with genetic context is the consistent thread of its approach.

Why precise numbers matter here

With a medication dosed in fractions of a milligram, a single dropped decimal changes the meaning entirely, and "25 mg" is the classic example. Confirming the exact figure on your own label, rather than relying on memory or a hurried screenshot, is a small habit that prevents real confusion. When in doubt, the pharmacy label and your clinician are the two authoritative sources, and either can settle which point on the ladder you are actually asking about.

Frequently Asked Questions

Is there really a 25 mg Wegovy dose?

No. Wegovy is dosed in small single-digit milligram amounts on a schedule that runs from 0.25 mg up to 2.4 mg. A plain "25 mg" is almost certainly a misread of one of those figures, most often 0.25 mg with a dropped decimal. Confirm the exact strength on your label or with your clinician.

What are the actual Wegovy strengths?

The labeled titration ladder uses 0.25, 0.5, 1.0, 1.7, and 2.4 mg, with 2.4 mg serving as the maintenance dose. Each is a precise point the FDA label defines. Reading these exactly, decimal points included, is the surest way to avoid the number confusion that "25 mg" searches usually reflect.

Does the genetic test predict my response at a given strength?

No. The Precision Peptide Genetic Test does not forecast your reaction to any dose. It analyzes pathway-level variants such as FTO, GLP1R, MC4R, and TCF7L2 tied to appetite and energy biology, providing context that applies across the whole schedule rather than a prediction about any single strength.

What side effects show up across the schedule?

Gastrointestinal symptoms are the most common at any step, including nausea, vomiting, diarrhea, and constipation, usually strongest just after a change. Contact a provider for severe abdominal pain, persistent vomiting with dehydration, right-upper-quadrant pain with fever, or an allergic reaction. The class carries a boxed warning for thyroid C-cell tumor risk.

This explainer lives in the PlexusDx Education Hub. Browse every Peptides & GLP-1 guide for the wider library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.